Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What is the Projected CAGR for the Intussusception Market Size from 2025 to 2034?
The market size of intussusception has been continuously expanding over recent years. The growth is projected to rise from $4.45 billion in 2024 to $4.67 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 4.8%. Factors contributing to growth during the historical period include advancements in diagnostic techniques, heightened awareness and education, expansion of global healthcare infrastructure, investment in research and development, and cooperation between healthcare organizations.
The intussusception market size is expected to see steady growth in the next few years. It will grow to $5.46 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to continued medical education initiatives, pediatric vaccination programs, global efforts in pediatric healthcare, focus on postoperative care, rising demand for pediatric gastrointestinal research, telemedicine and remote healthcare access. Major trends in the forecast period include advancements in diagnostic imaging, minimally invasive treatment approaches, development of pediatric-specific interventions, research on etiology and risk factors, global epidemiological studies, implementation of vaccination programs, telemedicine for diagnosis and consultation.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13466&type=smp
What are the Fundamental Drivers and Innovations Shaping the Intussusception Market?
Escalating occurrences of intestinal troubles are predicted to stimulate the expansion of the intussusception market in the future. An intestinal malfunction is characterized by any health complication or ailment that interferes with the regular operation of the intestines- a primary component of the digestive system that aids in nutrient absorption and waste elimination. The augmenting prevalence of intestinal troubles including inflammatory bowel malady and gastrointestinal cancers can result in advanced diagnosis, upgraded therapy alternatives, and considerable backup for intussusception patients, which collectively enhances their health and quality of life. For example, as noted by the American Cancer Society (ACS), an organization based in the US committed to eradicating cancer, the occurrence of gastrointestinal cancers saw an increase of 3.18% to 348,840 in January 2023 from 338,090 in 2021 within the United States. Consequently, the increasing pattern of intestinal disorders is anticipated to fuel the intussusception market’s growth.
How Is the Intussusception Market Segmented?
The intussusceptionmarket covered in this report is segmented –
1) By Type: Idiopathic Intussusception; Secondary Intussusception
2) By Treatment: Enema Reduction; Surgery; Other Treatment
3) By Diagnosis: Barium Enema; Ultrasound; X-Ray; Computerized Tomography (CT)
4) By End-User: Hospitals; Clinics; Other End-User
Subsegments:
1) By Idiopathic Intussusception: Childhood Idiopathic Intussusception; Adult Idiopathic Intussusception
2) By Secondary Intussusception: Neoplastic Intussusception; Infectious Intussusception; Inflammatory Intussusception; Post-Surgical Intussusception
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13466&type=smp
Which Regions Are Driving the Next Phase of the Intussusception Market Growth?
North America was the largest region in the intussusception market in 2024. The regions covered in the intussusception market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Intussusception Market?
Leading enterprises in the intestinal pseudo-obstruction treatment market are pioneering innovative drug treatments, such as NHE3 inhibitor treatment therapy, to ensure reliable service for consumers. The NHE3 inhibitor treatment functions by suppressing the Sodium-Proton-Exchanger subtype 3 (NHE3) in the digestive tract. For example, Ardelyx Inc., a biopharmaceutical firm based in the US, launched IBSRELA in April 2022. It’s an NHE3 inhibitor treatment designed for adults with irritable bowel syndrome complicated by constipation (IBS-C), potentially enhancing gut motility. The action mechanism of IBSRELA involves impeding or blocking the Sodium-Hydrogen Exchanger 3 (NHE3) protein. The endorsement of IBSRELA was built upon two phase 3 clinical trials involving more than 1,200 IBS-C patients. The drug showed a notable improvement in abdominal discomfort and bowel regulation, meeting the main objective. These enhancements were noticeable as early as the first week and continued throughout the 26-week-long study.
View the full report here:
https://www.thebusinessresearchcompany.com/report/intussusception-global-market-report
How Is the Intussusception Market Defined and What Are Its Core Parameters?
Intussusception is a medical condition in which one portion of the intestine slides into an adjacent section of the intestine, blocking the flow of food, fluids, and gas through the affected part of the intestine, leading to symptoms such as severe abdominal pain, vomiting, and bloody stools. It is usually diagnosed based on the symptoms, physical examination, and imaging tests.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13466
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model